Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449146 | 0.81 | PTGS2 (0.49) | SMN1; SMN2KMT2ANPC1RAB9ATP53 | |
| SCHEMBL28720579 | 0.80 | LMNA (0.44) | LMNAPTGS2PTGS1PKMCA1 | |
| SCHEMBL5108030 | 0.80 | LMNA (0.40) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL2415480 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL12896114 | 0.77 | GCK (0.38) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL32665217 | 0.77 | LMNA (0.34) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL23036852 | 0.75 | KIF11 (0.40) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL1550685 | 0.75 | TLR9 (0.48) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL3648380 | 0.75 | TLR9 (0.39) | SMN1; SMN2LMNAKMT2ANPC1TLR9 | |
| SCHEMBL27773731 | 0.75 | MAPT (0.44) | SMN1; SMN2LMNAKMT2ANPC1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| WO-2003055863-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-10 | — | — | WO | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | SMN1; SMN2 4142/4885LMNA 4042/4885KMT2A 2280/4885 |
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | SMN1; SMN2 4627/4885LMNA 2329/4885KMT2A 4504/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | SMN1; SMN2 3406/4885LMNA 2566/4885KMT2A 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.